Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.63 |
| ▸ | HTR6 | P50406 | 9/20 | 0.59 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10123303 | 0.92 | HTR6 (0.59) | THRBHTR6TP53MAPTRXFP1 | |
| SCHEMBL10123256 | 0.89 | THRB (0.64) | THRBHTR6TP53MAPTRXFP1 | |
| SCHEMBL667284 | 0.88 | THRB (0.79) | THRBHTR6TP53MAPTRXFP1 | |
| SCHEMBL10123316 | 0.88 | THRB (0.63) | THRBHTR6TP53MAPTRXFP1 | |
| SCHEMBL8029045 | 0.87 | KDM4E (0.61) | THRBHTR6TP53MAPTRXFP1 | |
| SCHEMBL10123317 | 0.86 | THRB (0.61) | THRBHTR6TP53MAPTRXFP1 | |
| SCHEMBL10123311 | 0.86 | THRB (0.61) | THRBHTR6TP53MAPTRXFP1 | |
| SCHEMBL13573198 | 0.85 | THRB (0.60) | THRBHTR6TP53MAPTRXFP1 | |
| SCHEMBL10123297 | 0.85 | THRB (0.61) | THRBHTR6TP53MAPTRXFP1 | |
| SCHEMBL10123264 | 0.84 | THRB (0.58) | THRBHTR6TP53MAPTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303888-B1 | COMPOUNDS FOR ANTIMICROBIAL INTERVENTION | HARVARD COLLEGE (US) | 2015-05-06 | — | — | EP | disclosed |
| US-20120046282-A1 | METHODS AND COMPOUNDS FOR ANTIMICROBIAL INTERVENTION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046282-A1 | METHODS AND COMPOUNDS FOR ANTIMICROBIAL INTERVENTION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2009151561-A2 | METHODS AND COMPOUNDS FOR ANTIMICROBIAL INTERVENTION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046282-A1 | METHODS AND COMPOUNDS FOR ANTIMICROBIAL INTERVENTION | FDFT1, COASY, KAT5 | THRB 2096/4885HTR6 4755/4885TP53 4676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.